Advertisement

Diagnostic Approach

  • Marko Duvnjak
  • Nina Blažević
Chapter
Part of the Clinical Gastroenterology book series (CG)

Abstract

Non-alcoholic fatty liver disease (NAFLD) with its two clinically different entities [non-alcoholic fatty liver disease (NAFL) and non-alcoholic steatohepatitis (NASH)] is a condition affecting an increasing number of people worldwide, predominantly diagnosed with non-invasive imaging techniques. Serological testing can be subdivided into three groups based on the stage of NAFLD and includes several tests: SteatoTest, NAFLD fibrosis score and ultrasonographic fatty liver indicator. Cytokeratin-18 is the single serologic test most studied so far regarding the diagnosis of NASH. Non-invasive imaging techniques include ultrasonography as the first frontier in the diagnostic algorithm, transient elastography (FibroScan) and acoustic radiation force impulse (ARFI) elastography as important tools used to determine the extent of the liver stiffness, and computed tomography (CT)/magnetic resonance imaging (MRI). However, liver biopsy still remains the gold standard for the diagnosis and classification standards of NAFLD, though this procedure should only be used when there is lack of more beneficial alternatives, due to its invasiveness and potential risks. It is important to say that patients have to be evaluated periodically and efficiently assessed in order to determine treatment results and lifestyle changes that have to be made to manage hepatic steatosis and other further complications.

Keywords

Non-alcoholic fatty liver Steatohepatitis Serological testing Non-invasive imaging techniques Liver biopsy 

References

  1. 1.
    Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37:81–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMedGoogle Scholar
  4. 4.
    Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20(27):9072–89.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010;182:E526–31.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.CrossRefPubMedGoogle Scholar
  9. 9.
    Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–49.CrossRefPubMedGoogle Scholar
  11. 11.
    Lăpădat AM, Jianu IR, Ungureanu BS, Florescu LM, Gheonea DI, Sovaila S, Gheonea IA. Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. J Med Life. 2017;10(1):19–26.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Glen J, Floros L, Day C, Pryke R. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016;354:i4428.CrossRefPubMedGoogle Scholar
  13. 13.
    Oh H, Jun DW, Saeed WK, Nguyen MH. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment. Clin Mol Hepatol. 2016;22(3):327–35.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol. 2005;4:10.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167–74.CrossRefPubMedGoogle Scholar
  16. 16.
    Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, Senni-Buratti M, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010;32:1315–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.CrossRefPubMedGoogle Scholar
  19. 19.
    Ballestri S, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;72:57–65.CrossRefPubMedGoogle Scholar
  20. 20.
    Sporea I, Mare R, Lupușoru R, Sima A, Sirli R, Popescu A, Timar R. Liver stiffness. Liver stiffness evaluation by transient elastography in type 2 diabetes mellitus patients with ultrasound-proven steatosis. J Gastrointestin Liver Dis. 2016;25(2):167–74.PubMedGoogle Scholar
  21. 21.
    Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res. 2015;45(2):142–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Orlacchio A, Bolacchi F, Antonicoli M, Coco I, Costanzo E, Tosti D, Francioso S, Angelico M, Simonetti G. Liver elasticity in NASH patients evaluated with real-time elastography (RTE). Ultrasound Med Biol. 2012;38:537–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, Vauthey JN, Charnsangavej C. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007;188:1307–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, Ha HK, Lee MG, Hwang S, Lee SG, Yu ES, Cho EY. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105–12.CrossRefPubMedGoogle Scholar
  26. 26.
    Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230:276–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Machann J, Thamer C, Schnoedt B, Stefan N, Haring HU, Claussen CD, Fritsche A, Schick F. Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med. 2006;55:913–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Raptis DA, Fischer MA, Graf R, Nanz D, Weber A, Moritz W, Tian Y, Oberkofler CE, Clavien PA. MRI: the new reference standard in quantifying hepatic steatosis? Gut. 2012;61:117–27.CrossRefPubMedGoogle Scholar
  29. 29.
    Brunt ME. Nonalcoholic fatty liver disease: pros and cons of histologic systems of evaluation. Int J Mol Sci. 2016;17(1):97.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Marko Duvnjak
    • 1
    • 2
  • Nina Blažević
    • 1
  1. 1.Department of Gastroenterology and HepatologySestre milosrdnice University Hospital CenterZagrebCroatia
  2. 2.University of Zagreb School of MedicineZagrebCroatia

Personalised recommendations